Bank of New York Mellon’s TherapeuticsMD TXMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-20,994
| Closed | -$399K | – | 4701 |
|
|
2022
Q1 | $399K | Hold |
20,994
| – | – | ﹤0.01% | 3846 |
|
|
2021
Q4 | $373K | Buy |
20,994
+1,062
| +5% | +$31.8K | ﹤0.01% | 3970 |
|
|
2021
Q3 | $739K | Buy |
19,932
+489
| +3% | +$21.7K | ﹤0.01% | 3577 |
|
|
2021
Q2 | $1.16M | Sell |
19,443
-4,317
| -18% | -$262K | ﹤0.01% | 3312 |
|
|
2021
Q1 | $1.59M | Buy |
23,760
+3,706
| +18% | +$290K | ﹤0.01% | 3054 |
|
|
2020
Q4 | $1.21M | Buy |
20,054
+1,847
| +10% | +$126K | ﹤0.01% | 3153 |
|
|
2020
Q3 | $1.44M | Sell |
18,207
-217
| -1% | -$17.3K | ﹤0.01% | 2886 |
|
|
2020
Q2 | $1.15M | Sell |
18,424
-235,203
| -93% | -$13.7M | ﹤0.01% | 3021 |
|
|
2020
Q1 | $13.4M | Sell |
253,627
-8,755
| -3% | -$868K | ﹤0.01% | 1531 |
|
|
2019
Q4 | $31.7M | Sell |
262,382
-47,328
| -15% | -$6.8M | 0.01% | 1267 |
|
|
2019
Q3 | $56.2M | Sell |
309,710
-113,284
| -27% | -$16M | 0.02% | 877 |
|
|
2019
Q2 | $55M | Sell |
422,994
-59,899
| -12% | -$10.7M | 0.02% | 915 |
|
|
2019
Q1 | $118M | Sell |
482,893
-127,094
| -21% | -$33.6M | 0.03% | 504 |
|
|
2018
Q4 | $116M | Buy |
609,987
+4,269
| +0.7% | +$1.04M | 0.04% | 453 |
|
|
2018
Q3 | $199M | Sell |
605,718
-3,428
| -0.6% | -$1.05M | 0.05% | 353 |
|
|
2018
Q2 | $190M | Sell |
609,146
-37,812
| -6% | -$11.6M | 0.05% | 357 |
|
|
2018
Q1 | $158M | Buy |
646,958
+67,485
| +12% | +$18.9M | 0.04% | 416 |
|
|
2017
Q4 | $175M | Buy |
579,473
+61,916
| +12% | +$17.2M | 0.05% | 406 |
|
|
2017
Q3 | $137M | Buy |
517,557
+59,717
| +13% | +$17.3M | 0.04% | 460 |
|
|
2017
Q2 | $121M | Buy |
457,840
+51,482
| +13% | +$12.9M | 0.03% | 502 |
|
|
2017
Q1 | $146M | Sell |
406,358
-15,910
| -4% | -$4.92M | 0.04% | 443 |
|
|
2016
Q4 | $122M | Buy |
422,268
+110,583
| +35% | +$34.3M | 0.04% | 491 |
|
|
2016
Q3 | $106M | Sell |
311,685
-2,927
| -0.9% | -$1.07M | 0.03% | 517 |
|
|
2016
Q2 | $134M | Buy |
314,612
+59,088
| +23% | +$24.4M | 0.04% | 418 |
|
|
2016
Q1 | $81.8M | Buy |
255,524
+23,341
| +10% | +$7.96M | 0.02% | 641 |
|
|
2015
Q4 | $120M | Buy |
232,183
+2,694
| +1% | +$995K | 0.04% | 457 |
|
|
2015
Q3 | $67.2M | Buy |
229,489
+19,414
| +9% | +$6.9M | 0.02% | 703 |
|
|
2015
Q2 | $82.6M | Sell |
210,075
-2,823
| -1% | -$996K | 0.02% | 666 |
|
|
2015
Q1 | $64.4M | Buy |
212,898
+14,118
| +7% | +$3.45M | 0.02% | 782 |
|
|
2014
Q4 | $44.2M | Sell |
198,780
-7,101
| -3% | -$1.46M | 0.01% | 955 |
|
|
2014
Q3 | $47.8M | Buy |
205,881
+48,469
| +31% | +$12.2M | 0.01% | 897 |
|
|
2014
Q2 | $34.8M | Buy |
157,412
+68,079
| +76% | +$15.1M | 0.01% | 1117 |
|
|
2014
Q1 | $28.2M | Buy |
89,333
+82,075
| +1,131% | +$26.1M | 0.01% | 1249 |
|
|
2013
Q4 | $1.89M | Buy |
7,258
+2,196
| +43% | +$481K | ﹤0.01% | 2925 |
|
|
2013
Q3 | $741K | Sell |
5,062
-27
| -0.5% | -$3.27K | ﹤0.01% | 3394 |
|
|
2013
Q2 | $771K | Buy |
+5,089
| New | +$697K | ﹤0.01% | 3324 |
|
Other funds holding TXMD
RCMNY
E
GF
Bank of New York Mellon's TXMD Position: Q2 2022 in Review
Bank of New York Mellon sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 20,994 shares — an estimated $399K sold.
Bank of New York Mellon first reported a position in TXMD in Q2 2013 and held it in 36 quarters. The position peaked at $199M in Q3 2018. 52 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.
- Bank of New York Mellon reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
- Bank of New York Mellon sold 20,994 TherapeuticsMD shares in Q2 2022, an estimated $399K.
- Bank of New York Mellon first reported a position in TherapeuticsMD in Q2 2013 and held it in 36 quarters.
- Bank of New York Mellon's TherapeuticsMD position peaked at $199M in Q3 2018.
- 52 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.
Based on Bank of New York Mellon's 13F filing for Q2 2022, filed 15 Aug 2022.